rs387906312
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_001378454.1(ALMS1):c.10772delC(p.Thr3591LysfsTer6) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000318 in 1,613,968 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. T3591T) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001378454.1 frameshift
Scores
Clinical Significance
Conservation
Publications
- Alstrom syndromeInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, PanelApp Australia, G2P, Orphanet, Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000328 AC: 5AN: 152208Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000523 AC: 13AN: 248706 AF XY: 0.0000371 show subpopulations
GnomAD4 exome AF: 0.000348 AC: 509AN: 1461760Hom.: 0 Cov.: 32 AF XY: 0.000319 AC XY: 232AN XY: 727164 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152208Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74356 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Alstrom syndrome Pathogenic:6
This sequence change creates a premature translational stop signal (p.Thr3592Lysfs*6) in the ALMS1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALMS1 are known to be pathogenic (PMID: 17594715). This variant is present in population databases (rs387906312, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with ALMS1-related conditions (PMID: 11941369, 11941370, 25846608). ClinVar contains an entry for this variant (Variation ID: 3971). For these reasons, this variant has been classified as Pathogenic. -
- -
Variant summary: ALMS1 c.10769delC (p.Thr3590LysfsX6) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 5.2e-05 in 248706 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in ALMS1 causing Alstrom Syndrome (5.2e-05 vs 0.0014), allowing no conclusion about variant significance. The variant, c.10769delC (aka c.10775delC) has been reported in the literature in several individuals affected with Alstrom Syndrome (e.g. Marshall_2007, Marshall_2015). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 17594715, 25846608). ClinVar contains an entry for this variant (Variation ID: 3971). Based on the evidence outlined above, the variant was classified as pathogenic. -
- -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
The heterozygous p.Thr3590LysfsTer6 variant in ALMS1 was identified by our study, along with another pathogenic variant, in 1 individual with Alstrom syndrome. The variant has been reported in at least 9 individuals of British and unknown ethnicity with Alstrom syndrome (PMID: 28610912, 26704672, 28112973, 11941369, 11941370), and has been identified in 0.01% (13/128100) of European non-Finnish chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs387906312). Although this variant has been seen in the general population, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID: 3971) as pathogenic by multiple submitters. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 3590 and leads to a premature termination codon 6 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the ALMS1 gene is an established disease mechanism in autosomal recessive Alstrom syndrome. The presence of this variant in at least 3 affected homozygotes, in combination with reported likely pathogenic variants, and in at least 9 individuals with Alstrom syndrome increases the likelihood that the p.Thr3590LysfsTer6 variant is pathogenic (Variation ID: 871762, 210129; PMID: 28610912, 26704672, 28112973, 11941369, 11941370). In summary, the p.Thr3590LysfsTer6 variant is pathogenic based of the predicted loss of function effect and the presence of multiple homozygotes and other pathogenic variants found in combination with this variant in affected individuals. ACMG/AMP Criteria applied: PVS1, PM3_strong (Richards 2015). -
not provided Pathogenic:2
Not observed at a significant frequency in large population cohorts (gnomAD); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 21897446, 11941370, 11941369, 17594715, 21157496, 25846608, 26066530, 26104972, 26704672, 28610912, 32503575, 16720663) -
- -
Cardiovascular phenotype Pathogenic:1
The c.10775delC pathogenic mutation, located in coding exon 16 of the ALMS1 gene, results from a deletion of one nucleotide at nucleotide position 10775, causing a translational frameshift with a predicted alternate stop codon (p.T3592Kfs*6). This variant has been detected in the homozygous state and in the compound heterozygous state with other ALMS1 variants in several individuals reported to have Alström syndrome (AS), features consistent with AS, or in AS cohorts (Collin GB et al. Nat Genet, 2002 May;31:74-8; Hearn T et al. Nat Genet, 2002 May;31:79-83; Marshall JD et al. Hum Mutat, 2007 Nov;28:1114-23; Pereiro I et al. Eur J Hum Genet, 2011 Apr;19:485-8; Marshall JD et al. Hum Mutat, 2015 Jul;36:660-8; Paisey RB et al. J Clin Endocrinol Metab, 2015 Aug;100:E1116-24; Waldman M et al. Mol Genet Metab, 2018 Sep;125:181-191). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Retinal dystrophy Pathogenic:1
- -
Bardet-Biedl syndrome Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at